Literature DB >> 8394864

Depression of the immune response to an inactivated hepatitis A vaccine administered concomitantly with immune globulin.

M S Green1, D Cohen, Y Lerman, M Sjogren, L N Binn, S Zur, R Slepon, G Robin, C Hoke, W Bancroft.   

Abstract

Inactivated hepatitis A virus (HAV) vaccine is given in a three-dose schedule. When rapid protection is needed, injection of immune globulin (IG) concomitantly with the first dose could provide passive protection until adequate active antibody response has developed. A possible effect of IG on the immune response to the vaccine was studied in healthy volunteers; 28 received vaccine alone, and 34 received the first dose simultaneously with 5 mL of IG. A control group received hepatitis B vaccine, and a fourth group received IG alone. Four weeks after the first vaccine dose, all subjects had detectable ELISA anti-HAV antibodies. Several weeks after each vaccine dose, the geometric mean titer of antibodies was significantly lower in those who received vaccine with IG but higher than in those who received IG alone. Results for neutralizing antibodies yielded a similar trend. If IG is given with HAV vaccine, a further booster vaccine dose may be required to ensure long-lasting immunity.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8394864     DOI: 10.1093/infdis/168.3.740

Source DB:  PubMed          Journal:  J Infect Dis        ISSN: 0022-1899            Impact factor:   5.226


  11 in total

1.  Preventing hepatitis A infections. National Advisory Committee on Immunization statement. Laboratory Centre for Disease Control.

Authors: 
Journal:  Can Fam Physician       Date:  1995-07       Impact factor: 3.275

2.  Neutralizing antibodies protect against lethal flavivirus challenge but allow for the development of active humoral immunity to a nonstructural virus protein.

Authors:  T R Kreil; E Maier; S Fraiss; M M Eibl
Journal:  J Virol       Date:  1998-04       Impact factor: 5.103

3.  Supplementary statement on hepatitis A prevention. Laboratory Centre for Disease Control.

Authors: 
Journal:  CMAJ       Date:  1996-08-01       Impact factor: 8.262

Review 4.  Clinical development of a new inactivated hepatitis A vaccine.

Authors:  E Vidor; B Fritzell; S Plotkin
Journal:  Infection       Date:  1996 Nov-Dec       Impact factor: 3.553

5.  Decline of hepatitis A antibodies during the first 7 months of life in full-term and preterm infants.

Authors:  N Linder; Y Karetnyi; Y Gidony; R Dagan; G Ohel; E Levin; E Mendelson; A Barzilai
Journal:  Infection       Date:  1999 Mar-Apr       Impact factor: 3.553

Review 6.  New hepatitis A vaccines and their role in prevention.

Authors:  D B Strader; L B Seeff
Journal:  Drugs       Date:  1996-03       Impact factor: 9.546

Review 7.  Immunization against Hepatitis A.

Authors:  Daniel Shouval
Journal:  Cold Spring Harb Perspect Med       Date:  2019-02-01       Impact factor: 6.915

Review 8.  Hepatitis A: old and new.

Authors:  J A Cuthbert
Journal:  Clin Microbiol Rev       Date:  2001-01       Impact factor: 26.132

Review 9.  New developments in hepatitis A control.

Authors:  L Yuan
Journal:  Can Fam Physician       Date:  1995-07       Impact factor: 3.275

Review 10.  Aventis Pasteur vaccines containing inactivated hepatitis A virus: a compilation of immunogenicity data.

Authors:  E Vidor; R Dumas; V Porteret; F Bailleux; K Veitch
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2004-03-06       Impact factor: 3.267

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.